Press Releases

CNS Pharmaceuticals Completes Active Ingredient Shipments to Manufacturers

Jul 08, 2020 8:00am EDT

CNS Pharmaceuticals Engages Berry Consultants to Advise Phase 2 Trial Design

Jun 30, 2020 8:00am EDT

CNS To Present at the Life Sciences Investor Forum

Jun 23, 2020 8:00am EDT

CNS Announces the FDA has Granted Orphan Drug Designation for Brain Cancer Drug Berubicin

Jun 11, 2020 8:00am EDT

CNS Announces Highlights from Annual Meeting of Shareholders

Jun 09, 2020 8:00am EDT

CNS Pharmaceuticals Announces Sponsored Research Agreement with MD Anderson for Potential Cancer Treatment Technologies

May 28, 2020 8:00am EDT

CNS Announces Common Stock Will Resume Trading on the NASDAQ on May 28, 2020

May 27, 2020 6:00pm EDT

CNS Provides Update on Development Agreement for WP1122

May 27, 2020 4:10pm EDT

CNS Announces Nasdaq Trading Halt Pending Receipt of Additional Information

May 18, 2020 8:00am EDT

CNS Provides Additional Comments Regarding Trading Halt

May 11, 2020 8:00am EDT